RGEN - REPLIGEN CORP
IEX Last Trade
145.28
-0.470 -0.324%
Share volume: 0
Last Updated: Fri 27 Dec 2024 03:30:13 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.05%
PREVIOUS CLOSE
CHG
CHG%
$145.75
-0.47
-0.32%
Fundamental analysis
19%
Profitability
9%
Dept financing
33%
Liquidity
75%
Performance
12%
Performance
5 Days
0.89%
1 Month
0.14%
3 Months
-0.16%
6 Months
15.71%
1 Year
-19.97%
2 Year
-11.77%
Key data
Stock price
$145.28
DAY RANGE
N/A - N/A
52 WEEK RANGE
$120.98 - $211.13
52 WEEK CHANGE
-$20.72
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/29/2024
Company detail
CEO: Tony J. Hunt
Region: US
Website: repligen.com
Employees: 2,020
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: repligen.com
Employees: 2,020
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company sells its products to life sciences, biopharmaceutical companies; laboratory researchers; and contract manufacturing organizations.
Recent news